Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
企業コードZLAB
会社名Zai Lab Ltd
上場日Sep 28, 2020
最高経営責任者「CEO」Dr. Du (Samantha) Ying, Ph.D.
従業員数1869
証券種類Depository Receipt
決算期末Sep 28
本社所在地Building B, 899 Halei Road, Pudong
都市SHANGHAI
証券取引所NASDAQ Global Market Consolidated
国China
郵便番号201203
電話番号862161632588
ウェブサイトhttps://www.zailaboratory.com/
企業コードZLAB
上場日Sep 28, 2020
最高経営責任者「CEO」Dr. Du (Samantha) Ying, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし